Business Wire

Data Security Innovator, Secure Channels, Chooses Thales to Provide Key Management and Software Licensing Platform For IoT Security Solution

Share

Thales has announced its encryption key management and software licencing platforms have been chosen by Secure Channels to protect its quantum-resilient encryption keys for its IoT-enabled devices. By using Thales’ key management platform, both companies’ customers will benefit from increased data protection no matter the connected device, even if there is no current security protection in place. In addition, Thales’ software licensing platform will enable easy access to Secure Channels’ cybersecurity software technology for customers and manufacturers, thus ensuring all IoT devices can be protected easily either at source or retrospectively.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200121005189/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Thales)

“Thales’s Sentinel Entitlement Management Software has enabled the first generation of truly secure connected devices,” said Secure Channels Chief Executive Officer Richard Blech. “With the vast increase in the number of connected devices hitting the market recently, many are landing in the hands of users without any real protection. The Sentinel EMS tool has enabled our encryption to be launched, managed and distributed within very secure offline environments in addition to cloud-based connected devices protecting the multitude of data flowing within them.”

Thales’s enterprise key management platform provides secure storage for the larger-than-average encryption keys required for long-term data protection. Secure Channels’ XOTIC strong cryptosystem ranges in encryption strengths from 512-bit to more than 8,000-bit protection. XOTIC’s “bottom floor” is twice as strong as the prevalent 256-bit encryption that will have questionable efficacy against post-quantum attacks. The combined key management and evolved-encryption solution gives customers highly secure, archive-level data protection across each IoT-enabled device they develop and own.

Manufacturers are challenged with protecting user data transmitted and stored in devices with power, bandwidth and CPU constraints that preclude the use of adequate encryption. As the demand for the rate of connected devices has increased, this has resulted in a sub-optimal security that leaves the data vulnerable to malicious third parties. XOTIC’s ultralight-weight footprint and high-speed performance provide manufacturers a strong encryption solution that fits in their devices while preserving responsiveness.

The collaboration gives manufacturers and customers improved access to Secure Channels’ XOTIC via Thales’ software licensing platform, Sentinel EMS. This platform provides security benefits to manufacturers of devices that transmit sensitive user data, as increasing data privacy regulations assign liability and penalties for a failure to provide reasonable security protection.

The threat of quantum computing is something that could dominate the business world for years to come as the fear of its computing power is likely to grow,” said Sebastien Cano, senior vice president for cloud protection and licensing activities at Thales. “We’re delighted to partner with Secure Channels to put these fears to bed from now on by protecting any connected device no matter the level of protection they already have or don’t have, and enable companies to focus on innovating and progressing without a lingering doubt over the long-term futures of their sensitive data. It’s also vital that security is seen as easy to use and easily accessible, as provided by our licensing platform.”

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2018 (on a pro forma basis including Gem alto).

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments

PLEASE VISIT

Thales Group
Security
Download HD photos

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thales, Media Relations
Security
Constance Arnoux
+33 (0)1 57 77 91 58
constance.arnoux@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium4.11.2025 14:00:00 EET | Press release

Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas. The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC). “We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence cohort for early-stage breast cancer,” said William Audeh, M.D., Chief Medical Officer at Agendia. “These results underscore our commitment to generating robust clinical evi

Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer4.11.2025 14:00:00 EET | Press release

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy” in Nature Communications. This landmark study evaluated the HER2DX genomic assay in 154 individuals aged 70–80 years enrolled in the RESPECT trial (NCT01104935), a randomized phase III study comparing adjuvant trastuzumab with or without chemotherapy. The analysis, known as Trans-RESPECT, is the first to evaluate HER2DX in an older adult population, a demographic historically underrepresented in clinical trials. Bringing Precision Oncology to Older Individuals with HER2+ Disease Despite the growing number of older adults diagnosed with HER2-positive early breast cancer, optimal treatment strategies remain unclear. Many face increased risks of chemotherapy-related toxicit

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months4.11.2025 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 months,” said Kabir Nath, Chief Executive Officer at Compass Pathways. “We are accelerating commercial launch plans to match this new expected timeline with the goal of advancing our mission of transforming the mental health landscape and how patients living with depression are treated.” Business Highlights COMP360 psilocybin treatment in TRD (Treatment Resistant Depression) Second Phase 3 trial, COMP006, has completed enrollment (n=585) In June 2025, we announced achievement of the 6-week primary endpoint in the first of two phase 3

TELEO Capital Closes Oversubscribed TELEO Capital II at $350 Million Hard Cap4.11.2025 13:00:00 EET | Press release

TELEO Capital Management, LLC (“TELEO”), an operationally focused private equity firm focused on investing in lower middle market enterprise software companies, today announced the final close of TELEO Capital II (“Fund II”) at its hard cap of $350 million in Limited Partner capital commitments. Fund II was oversubscribed and attracted a diverse group of new and existing institutional investors. TELEO executes a time-tested strategy in the lower middle market, leveraging a large purpose-built team and repeatable process designed to deliver consistent, outsized returns. Fund II will continue TELEO’s focus on acquiring mission-critical software divisions of large corporations. TELEO is an ideal partner to large corporate sellers in need of a solution where speed and certainty to close, minimal post-closing distraction risk from shared services agreements, and a commitment to protecting customer and employee relationships are extremely important. “We are honored by the trust our investors

Celonis Partners with Databricks to Power Enterprise AI that Continuously Improves Business Operations4.11.2025 12:00:00 EET | Press release

Celonis, a global leader in Process Intelligence, today announced a partnership with Databricks, the Data and AI company, to provide customers with a seamless, powerful pathway to operationalize AI. The integration leverages Delta Sharing to directly connect the Celonis Process Intelligence Platform with the Databricks Data Intelligence Platform. Delta Sharing is Databricks’ open source approach that enables customers to share live data across platforms, clouds and regions with strong security and governance. This bi-directional integration, powered by Delta Sharing, eliminates the need to move or copy data between the two platforms. It breaks down data silos, reduces data copies, limits synchronization errors, enhances security, and simplifies data governance. With data and process intelligence flowing freely between the two platforms, customers get a continuous learning loop for AI-driven operations. Customers can use Celonis to read live data stored in Databricks and enrich it with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye